LEXINGTON, Mass.–(BUSINESS WIRE)–Dec 2, 2019– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia. CTP-692 is a deuterated form of...
BARCELONA, Spain, Dec. 2, 2019 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management...
JERSEY CITY, N.J., Dec. 2, 2019 /PRNewswire-PRWeb/ — TrialScope, the global leader in clinical trial transparency and disclosure compliance solutions, has worked with EMD Serono, the North American branch of the healthcare business of Merck KGaA,...
SUZHOU, China, Nov. 26, 2019 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent” or “the Company”) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of...
LOS ANGELES–(BUSINESS WIRE)–OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the...
Non-muscle-invasive bladder cancer (NMIBC) is the most common neoplasm of the urinary tract and requires life-long invasive surveillance to detect disease recurrence. Currently, there are no effective oral therapies that delay disease recurrence or progression. We...
Email
Text